share_log

Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10

Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10

Keybanc维持对健康催化剂的增持,将目标股价下调至10美元
Benzinga ·  02/26 05:19

Keybanc analyst Scott Schoenhaus maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $12 to $10.

Keybanc分析师斯科特·舍恩豪斯维持Health Catalyst(纳斯达克股票代码:HCAT)增持,并将目标股价从12美元下调至10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发